4.8 Article

Paper-based electrochemiluminescence sensor for highly sensitive detection of amyloid-β oligomerization: Toward potential diagnosis of Alzheimer's disease

期刊

THERANOSTICS
卷 8, 期 8, 页码 2289-2299

出版社

IVYSPRING INT PUBL
DOI: 10.7150/thno.23483

关键词

A beta(1-42) aggregation; electrochemiluminescence; [Ru(phen)(2)dppz](2+); paper-based bipolar electrode; Alzheimer's disease

资金

  1. National Natural Science Foundation of China [21475048]
  2. National Science Fund for Distinguished Young Scholars of Guangdong Province [2014A030306008]
  3. Project of Guangzhou Science and Technology Plan [201508020003]
  4. Program of the Pearl River Young Talents of Science and Technology in Guangzhou [2013J2200021]
  5. Special Support Program of Guangdong Province [2014TQ01R599]
  6. Outstanding Young Teacher Training Program of Guangdong Province [HS2015004]

向作者/读者索取更多资源

Development of a rapid and sensitive method for A beta(1-42) aggregation detection is of great importance to overcome the limitations of conventional techniques. In this study, we developed a label-free paper-based electrochemiluminescence sensor for amyloid-beta aggregation detection toward potential diagnosis of Alzheimer's disease (AD). The paper-based chip used in the system serves as a low-cost and disposable detection method. In this detection platform, the bonding of [Ru(phen)(2)dppz](2+) to A beta(1-42) aggregates results in enhanced electrochemiluminescence due to the change in the polarity of the microenvironment when [Ru(phen)(2)dppz](2+) intercalated into the beta-sheets during oligomerization. The oligomerization process of A beta(1-42) can be monitored in real time by the novel method, and as low as 100 pM equivalent monomer concentration of A beta(1-42) could be detected simultaneously. In addition, the cerebrospinal fluid of transgenic AD model mice was tested by this method, which is highly consistent with genetic identification. In addition, we demonstrated that this detection platform could be a potential new method for the screening of A beta(1-42) aggregation inhibitors, highlighting the practical application capacity of this platform. The platform is label free, low cost and sensitive. Therefore, the proposed platform holds great promise for the diagnosis of AD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据